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Although mouse models have been valuable for
studying human disease, the cellular and physiolog-
ical differences between mouse and human have
made it increasingly important to develop more rele-
vant human disease models for mechanistic studies
and drug discovery. Human embryonic stem cells
(hESCs), which can undergo unlimited self-renewal
and retain the potential to differentiate into all cell
types, present a possible solution. To improve the
efficiency of genetic manipulation of hESCs, we
have developed bacterial artificial chromosome
(BAC) based approach that enables high efficiency
homologous recombination. By sequentially disrupt-
ing both alleles of ATM or p53 with BAC targeting
vectors, we have established ATM/ and p53/
hESCs as models for twomajor human genetic insta-
bility syndromes and used the generated cells to
reveal the importance of p53 in maintaining genome
stability of hESCs. Our findings suggest that it will
be feasible to develop genetically modified hESCs
as relevant human disease models.
INTRODUCTION
Mouse knockin and knockout technologies have allowed the
generation of mouse models for human genetic diseases,
studies of which have provided considerable mechanistic
insight on the pathogenesis of human diseases. However,
many apparent cellular and physiological differences between
mouse and human make it difficult for mouse models to recapit-
ulate all mechanisms of pathogenesis in human patients and
lead to the common phenomenon that therapeutic interventions
work well in mouse models but poorly in human patients. There-
fore, there is an increasing demand for more relevant human
disease models. Human embryonic stem cells (hESCs) are
capable of unlimited self-renewal and retain the pluripotency
to differentiate into all cell types of the human body in vitro
and in vivo. Therefore, the disease-specific hESCs could
provide the much-needed human disease models that are80 Cell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc.complementary to mouse models for mechanistic studies and
drug discovery.
Despite the great potential of hESCs in modeling human
genetic diseases, this area of research has been largely stalled
due to the technical difficulty in genetically modifying hESCs.
While a number of reported studies have used standard plasmid
vectors to target endogenous genes through homologous
recombination in hESCs (Urbach et al., 2004; Costa et al.,
2007; Davis et al., 2008; Xue et al., 2009; Irion et al., 2007;
Ruby and Zheng, 2009; Zwaka and Thomson, 2003), the target-
ing efficiency is usually low. In addition, there have been few
successes of homozygous disruption of a gene in hESCs. To
address this bottleneck, we have adapted and optimized the
bacterial artificial chromosome (BAC)-based targeting approach
that routinely enables high efficiency homologous recombination
in hESCs. As a proof of principles, we have employed this BAC-
based targeting approach to generate ATM/ and p53/
hESCs that provide the disease models for two major human
cancer and genetic instability syndromes.
ATM is a protein kinase mutated in the human genetic insta-
bility syndrome Ataxia-telangiectasia (Lara-Tejero and Gala´n,
2000), which is characterized by multisystemic defects,
including growth retardation, neuronal degeneration, telangiec-
tasia, male and female germ cell defects, immunodeficiency,
greatly increased cancer risk and hypersensitivity to ionizing
radiation (Shiloh, 1995). A-T cells undergo reduced proliferation
and premature senescence and are radiosensitive with in-
creased genetic instability, such as chromosomal translocation
(Shiloh and Kastan, 2001). To investigate the physiological
roles of ATM in DNA-damage responses and mammalian devel-
opment, ATM-deficient mice have been established that recapit-
ulate many A-T systemic and cellular defects, including radio-
sensitivity, immunodeficiency, high incidence of cancer, and
abolished germ cell development (Barlow et al., 1996; Elson
et al., 1996; Xu et al., 1996; Xu and Baltimore, 1996). However,
several A-T-related defects, such as apparent neuronal degen-
eration and accelerated shortening of telomeres, are not evident
in ATM-deficient mice.
p53 is the most commonly mutated tumor suppressor in
human cancers and plays critical roles in cell-cycle arrest,
cellular differentiation and apoptosis, and DNA repair (Mills,
2005). All these functions of p53 are important to maintain
genetic stability by preventing the genome from accumulating
mutations and passaging these mutations to the daughter cells.
Cell Stem Cell
Genetic Manipulation of Human ESCsp53 is a transcription factor with a sequence-specific DNA-
binding domain in the central region and a transcriptional activa-
tion domain at the N-terminus (Ko and Prives, 1996). Three
additional domains, including a nuclear localization signal, a
tetramerization domain, and an extreme C-terminal regulatory
domain, are present in the C terminus of p53 (Ko and Prives,
1996). For over a decade, p53/ mice have been used exten-
sively in cancer research. However, p53/ mice fail to recapitu-
late the tumorigenesis in human patients. In this context, while
p53/mice uniformly died of thymic lymphomas and sarcomas
(Donehower et al., 1992; Jacks et al., 1994), human cancer
patients mostly develop carcinomas. In addition, while p53 is
required for G2/M checkpoint in human cells, it is dispensable
for G2/M checkpoint in mouse cells (Sancar et al., 2004; Song
et al., 2007). Therefore, the ATM/ and p53/ hESCs provide
unique opportunity to further study the roles of these critical
tumor suppressors in maintaining genetic stability in hESCs
and tumor suppression in humans.
RESULTS
Targeted Disruption of the ATM Gene in hESCs
with BAC-Based Vectors
Based on our experience with genetic manipulation in mouse
ESCs, the capability of a single hESC to undergo self-renewal
and expand into an entire colony without incurring differentiation
and genetic instability is a prerequisite for the success of genetic
manipulation. After experimenting with the existing hESC lines,
we found that the HUES lines, which can be passaged as single
cells, are suitable for this purpose (Cowan et al., 2004). To disrupt
the ATM gene in hESCs, we initially constructed a conventional
targeting vector with limited sizes (9 Kb and 2 kb) of homologous
arms. The very low targeting efficiency (<0.5%) makes it imprac-
tical to sequentially target both alleles of ATM in hESCs (data not
shown). To increase the frequency of homologous recombina-
tion in hESCs, we employed the recombineering technology to
develop bacterial artificial chromosome (BAC)-based targeting
vectors that harbor much larger size of homologous arms (Cope-
land et al., 2001). To ensure the disruption of the expression of
the targeted genes, a splicing acceptor was present between
the CAG promoter and neomycin resistance gene (Neo) to
disrupt the normal splicing of the targeted gene locus, leading
to a fusion of upstream exon and Neo (Figure 1B). In addition,
the CAG-Neo selection cassette dramatically suppresses the
expression of the targeted allele. To allow the screening of the
homologous recombinants by Southern blotting, the size of
one homologous arm of the BAC-targeting vector was shortened
with recombineering.
The linearized BAC-targeting vector was transfected into
hESCs and selected with G418 for 2 weeks. The surviving colo-
nies were individually picked and expanded, and genomic DNA
was screened for homologous recombination. We usually ob-
tained 10–50 colonies after electroporating 100 mg linearized
BAC vectors into 20 million HUES9 cells. Since standard PCR
assay cannot be used to identify the homologous recombinants
due to the large sizes of the flanking homologous arms, we de-
signed a ligation-mediated PCR that can be universally adapted
to screen homologous recombinants involving BAC-based
targeting vectors (Figure 1C). In this context, the genomic DNAof individual clones was digested with NcoI, whose restriction
site lies in the selection marker and the genomic DNA outside
the shorter homology arms, and religated (Figure 1C). When
amplified by nested PCR reactions with primers 3 and 4 followed
by primers 1 and 2, only the DNA from the homologous recombi-
nants would give rise to a 332 bp PCR product (Figure 1D). Three
of the 14 clones obtained from one round of electroporation were
positive for homologous recombination event, indicating a
greatly increased targeting frequency of 21%. The ATM+/
hESCs were confirmed to have normal karyotypes (Figure S1A
available online).
To target the remaining WT allele in ATM+/ hESCs, we used
the same BAC vector, except changing the selection cassette to
CAG-Neo-IRES-Puro so that the transfectants are resistant to
puromycin (Figure 1C). Neo was retained in the selection
cassette, as it is required to confer kanamycin resistance to
the bacteria that have undergone recombineering. The homolo-
gous recombinants were also screened by ligation-mediated
PCR with primers 4 and 6 followed with primers 1 and 5; only
homologous recombinant will give rise to a 531 bp PCR product
(Figures 1C and 1D). Ten of the 37 clones obtained from one
round of electroporation were positive for the homologous
recombination event, indicating a targeting efficiency of 27%.
In two of the ten positive clones, the WT allele was targeted to
generate homozygous mutant hESCs. The homozygous mutant
hESCs were confirmed by Southern blotting (Figure 1E). To
further ensure that there is no aberrant rearrangement between
the large homologous arm of BAC vector and the endogenous
locus, genomic DNA derived from ATM/ hESCs were
analyzed by Southern blotting with a mixture of probes spanning
throughout the long arm of the BAC vector, indicating that there
was no random integration or aberrant rearrangement (Fig-
ure S1B). Consistent with the lack of random integration in
ATM/ hESCs, we detected only two copies of the ATM loci
in ATM/ hESCs using a Taqman quantitative PCR assay (Fig-
ure S1C). In further support of the lack of random integration of
the targeting vector in ATM/ hESCs, SNP-CGH array analysis
showed no apparent alteration at the SNPs spanning the ATM
loci in ATM/ hESCs (Figure S1D). However, as a common
issue for all genetic manipulation approaches that require trans-
fection of exogenous DNA into hESCs, we cannot rule out the
possibility of the random integration of small DNA pieces of
the targeting vector into the genome. This issue could only be
addressed by whole genome sequencing of the targeted
hESCs.
To confirm that the expression of ATM is disrupted in ATM/
hESCs, the expression of ATM protein in the homozygous
mutant hESCs was analyzed, indicating that these mutant
hESCs are indeed ATM/ (Figure 1F).
Targeted Disruption of the p53 Gene in hESCs
To test whether the BAC-based approach can be employed to
efficiently target other locus, recombineering technology was
also used to develop BAC-based targeting vectors to disrupt
the p53 gene in hESCs (Figure 2B). To generate p53+/ hESCs,
WT hESCs were transfected with a BAC targeting vector that
was designed to delete exons 2–6 of human p53 (Figure 2B).
The targeting frequency was two in about 60 clones obtained
from two rounds of electroporation, and the homologousCell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc. 81
Figure 1. The Generation of ATM/ hESCs
(A) The endogenous ATM locus in humans. The
exons are indicated by open boxes. The initiation
ATG is located 85 Kb upstream from the exon
40. The size of the NcoI (N) restriction fragment
is indicated.
(B) BAC-based targeting vectors. In targeting
vector 1, the selection cassette CAG-Neo was in-
serted into intron 40 by recombineering. In target-
ing vector 2 used to target the WT allele in ATM+/
hESCs, the selection marker cassette CAG-Neo-
IRES-Puro was inserted into the same site of intron
40 by recombineering. The sizes of the homolo-
gous arms are indicated.
(C) The configuration of the both targeted ATM
alleles in ATM/ hESCs. The primers (P1–P6)
used to detect homologous recombination by liga-
tion-mediated PCR are indicated by arrowheads.
The sizes of the NcoI (N) restriction fragments of
both targeted alleles are indicated.
(D) Representative data of ligation-mediated PCR
to detect the targeting of both ATM alleles via
homologous recombination. Genomic DNA was
digested with NcoI, religated, and amplified by
nested PCR with primers P1–P6. Lane 1, WT
hESCs; Lane 2, hESCs in which the ATM allele
was targeted by vector 1; Lane 3, hESCs in which
the ATM allele was targeted by vector 2.
(E) Southern blotting analysis of WT (lane 1) and
ATM/ (lane 2) HUES9 hESCs. Genomic DNA
was digested with NcoI and hybridized with a
cDNA probe spanning exons 43–45. The restric-
tion fragments derived from WT and two targeted
alleles are indicated.
(F) The ATM protein is undetectable in ATM/
hESCs by western blotting analysis. ATM and the
loading control SMC1 are indicated.
(G) Southern blotting analysis of ATM+/ H9
hESCs as described in (E). Data from two indepen-
dent H9 ATM+/ clones are shown. See also
Figure S1.
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2D, and 2F). The relatively low targeting efficiency is likely due to
the relatively short homologous arms of the targeting vector.
After confirming that the p53+/ hESCs have normal a karyotype
(Figure S2A), the p53+/ hESCs were transfected with a BAC-
targeting vector that harbors longer homologous arms and
CAG-Neo-IRES-Puro selection cassette (Figure 2C). The homol-
ogous recombination between the targeting vector and the WT
allele in p53+/ hESCs were screened by PCR with primers
P1–P3 that amplify the targeted allele (P1 + P2) and theWT allele
(P1 + P3) in p53+/ hESCs (Figures 2D and 2E). If homologous
recombination occurs between the WT allele and the targeting
vector, there should be no amplification of the WT allele by
primers P1 + P3. Seven of the 32 clones obtained from one
round of electroporation had undergone homologous recombi-
nation between the WT allele and the targeting vector, giving
a targeting efficiency of 22% (Figure 2E). The homozygous
p53 mutant hESCs were confirmed by Southern blotting
(Figure 2F). To confirm that there was no aberrant rearrange-
ment between the longer arm of the BAC vector and the endog-
enous locus in the targeted hESCs, the genomic DNA from
heterozygous and homozygous mutant hESCs were also82 Cell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc.analyzed by Southern blotting with various enzymatic digestion
and hybridization to a mixture of probes within the targeting
vector, indicating no random integration of the targeting vector
or aberrant rearrangement (Figure S2B). The homozygous
mutant hESC clones have no detectable p53 protein even after
DNA damage that greatly increases p53 protein levels in WT
hESCs, confirming that these hESCs are indeed p53/
(Figure 2G).
BAC-Based Targeting Strategy Works Well
in Other hESC Lines and Genetic Loci
To test whether the BAC-based targeting strategy can be
applied to other hESC lines, we determined the targeting effi-
ciency of the BAC vector in disrupting the ATM gene in the
traditional hESC line H9. H9 cells were not suitable for clonal
selection because they must be passaged as clumps of cells
and undergo massive apoptosis when dissociated as single
cells. This problem was mitigated by a recent finding that a
ROCK inhibitor Y-27632 greatly increases cloning efficiency of
hESCs without affecting their pluripotency and genomic stability
(Watanabe et al., 2007). By treating the H9 hESCs with Y-27632
for 2 hours before electroporation and for 24 hr after
Figure 2. The Generation of p53/ hESCs
(A) The endogenous p53 locus in hESCs. The size
of NheI fragment is indicated. Open boxes repre-
sent exons. The initiating ATG is in exon 2.
(B) BAC-based targeting vector to delete exons
2–6 of human p53 gene. The sizes of flanking
homologous arms are indicated.
(C) BAC-based vector to target theWT p53 allele in
p53+/ hESCs. The selection marker cassette
CAG-Neo-IRES-Puro was inserted into the intron
4. The sizes of the flanking homologous arms
(80 kb and 81 kb) are indicated.
(D) The configuration of both targeted p53 alleles
in p53/ hESCs. The forward (P1) and two
reverse (P2 and P3) primers used for PCR
screening of homozygous targeting are indicated
by arrowheads.
(E) Representative PCR data to identify p53/
hESCs. Genomic DNA was amplified by PCR
with primers (P1 + P2 + P3). The targeting of the
WT allele in p53+/ hESCs leads to the loss of
any amplification by P1 + P3 due to the large
size of selection marker. The positive clones are
marked by asterisks. N.S. means nonspecific
PCR product.
(F) Genomic DNA of WT, p53+/, and p53/ was
digested with NheI and hybridized with a cDNA
probe spanning exons 5–10. The restriction frag-
ments derived from WT and two targeted alleles
are indicated.
(G) The p53 protein was undetectable in p53/
hESCs before and after DNA damage induced by
doxorubicin (0.2 mM). p53, Mdm2, and actin are
indicated. See also Figure S2.
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over 100 colonies from two rounds of electroporation. Sixteen
of the 76 clones screened were positive for homologous recom-
bination at the ATM locus, indicating a targeting efficiency of
21% (Figure 1G). Therefore, the BAC targeting vector can
achieve high efficiency of homologous recombination indepen-
dent of the genetic background of hESCs.
Both ATM and p53 are important in maintaining genomic
stability and regulating cell survival. To rule out the possibility
that the high targeting efficiency is due to the selection
for improved survival of hESCs impaired in ATM or p53, we
developed a BAC targeting vector to disrupt the X-linked
Hypoxanthine-Guanine Phosphoribosyl Transferase (HPRT)
gene (Figures 3A and 3B). To facilitate the analysis, the BAC
HPRT targeting vector was electroporated into HUES3 andCell Stem Cell 6, 80–8HUES8 hESCs, both of which are male
cells and, thus, have only one X chromo-
some. One of the three puromycin-resis-
tant HUES3 clones and one of the six
puromycin-resistant HUES8 clones
screened had theirHRPT gene disrupted,
indicating a high efficiency of gene
targeting with the HPRT BAC vector
(Figure 3C). As expected, HPRT knock-
out hESCs are hypersentitive to HAT
(Figure 3D). In summary, our findingsindicate that the efficient BAC targeting strategy is applicable
to various hESC lines and gene loci.
ATM/ hESCs and Fibroblasts Recapitulate
the Cellular Defects of A-T Patients
ATM deficiency leads to radiosensitivity and defective cell-cycle
checkpoints in A-T patients (Xu, 2006). Consistent with this
notion, ATM/ hESCs are hypersensitive to g-irradiation and
defective in G2/M checkpoint after IR (Figures 4A and 4B). In
addition, ATM-dependent phosphorylation of its targets,
including SMC1, CHK2, p53, and H2AX, is abolished after IR
(Figure 4C). Despite these apparent defects in DNA repair and
cell-cycle checkpoints, ATM/ hESCs exhibit normal karyo-
types (Figure S1E). In addition, SNP-CGH array analysis of
ATM/ hESCs indicated no apparent genomic alteration9, January 8, 2010 ª2010 Elsevier Inc. 83
Figure 3. Targeting HPRT Locus with a BAC Vector
(A) The endogenous locus of HPRT locus. Exons are represented by open
boxes.
(B) BAC targeting vector. The sizes of the homologous arms are shown. The
primers P1–P3 used for screening are indicated.
(C) Disruption of the HPRT gene in the male HUES3 and HUES8 hESCs that
have only one X chromosome. After the transfection of BAC vector into
HUES3 and -8, both of which are male, the transfectants were selected with
puromycin without any 6-TG counter selection to reveal the frequency of
homologous recombination. The homologous recombination event was
detected by PCR with primers P1–P3, giving rise to a 495 bp product from
the WT allele (P1 + P2) and a 393 bp product from the targeting vector or
targeted allele (P1 + P3). Homologous recombination between the targeting
vector and the only HPRT gene in hESCs leads to the loss of the WT PCR
product (lanes marked with asterisks). KO, HPRT knockout hESCs; vector,
BAC targeting vector.
(D) HPRT knockout hESCs are hypersensitive to Hypoxanthine-Aminopterin-
Thymidine (HAT). WT and HPRT knockout hESCs were plated onto 12-well
plate at a density of 104 cells/well, and 1 day later, mock-treated or selected
with medium containing 13 HAT (Sigma). Five days later, hESCs were visual-
ized by staining for alkaline phosphatase.
Figure 4. ATM-Dependent Cellular Responses to DNA DSB Damage
Are Abolished in ATM/ hESCs
(A) ATM/ hESCs are hypersensitive to IR.
(B) ATM/ hESCs are impaired in G2/M checkpoint after IR. Mean values from
three independent experiments are shown with standard derivation.
(C) ATM-dependent phosphorylation of SMC1 at Ser957, CHK2 at Thr68, p53
at Ser15, and H2AX at Ser139 (g-H2AX) is abolished in ATM/ hESCs after IR.
p53 stabilization after IR is impaired in ATM/ hESCs. Therefore, p53 protein
was stabilized with proteosome inhibitor ALLN. The phosphorylated and total
protein are indicated. Consistent data were obtained from two independent
ATM/ hESC clones.
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pendent pathways are sufficient to maintain genetic stability in
hESCs.
Thepower of hESCs inmodeling humandiseases is that hESCs
can be reproducibly differentiated into various primary cell types,
such as fibroblasts, for further study (Johnson et al., 2008). By
differentiating hESCs into fibroblasts using an EB-mediated
protocol (Figure 5A), we further characterized the ATM-depen-
dent responses to DNA damage in human fibroblasts. Irradia-
tion-induced foci formation (IRIF) of DNA repair proteins,
including phosphorylated ATM and H2AX (g-H2AX), is important
for initiating DNA DSB damage responses (Xu, 2006). IRIF of
phosphorylated ATM and H2AX is abolished in ATM/ fibro-
blasts (Figure 5B). Therefore, hESC-derived fibroblasts provide
another primary cell type that can be used to study the mecha-
nism of pathogenesis in A-T. In summary, these data demon-
strate that ATM/ hESCs and primary cells derived from them
recapitulate the cellular defects observed in A-T patients.84 Cell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc.In Vivo Differentiation of ATM/ hESCs
To confirm the hESC status of ATM/ hESCs, the ATM/
hESCs were analyzed for the expression of a panel of hESC-
specific surface markers, including TRA-1-60, SSEA3, and
SSEA4. This analysis indicates that ATM/ hESCs express
hESC-specific markers indistinguishably from the parental
hESCs (Figure S3A). When implanted into the severe combined
immunodeficient (SCID) mice, undifferentiated hESCs can form
well-differentiated teratomas-like mass that contains the cells
differentiated from each of the three germ layers (Thomson
et al., 1998). This provides an in vivo system to examine the plu-
ripotency of ATM/ hESCs and the roles of ATM in human
development. ATM/ hESC clones were injected subcutane-
ously into right side of the SCID mice. The same number of
parental WT hESCs was injected into the left side of the same
mice as an internal control. Like parental WT hESCs, ATM/
hESCs can give rise to teratomas-like mass that contain the cells
differentiated from each of the three embryonic germ layers, indi-
cating that the ATM/ hESCs are pluripotent (Figure 6A).
However, the size of the tumors derived from ATM/ hESCs is
about 30% of that derived from WT hESCs, indicating a growth
retardation phenotype similarly to that observed in A-T patients
(Figure 6B). Since ATM/ hESCs proliferate similarly to WT
parental hESCs, this growth retardation phenotype is not due
to any proliferative defects of ATM/ hESCs (Figure S3B).
A-T patients develop ataxia at a very young age, generally
thought as a result of Purkinje cell degeneration (Shiloh, 2003).
However, no apparent Purkinje cell degeneration can be
detected in ATM/ mice. To preliminarily test the role of
ATM in human neural development, we compared the neural
Figure 5. Human Fibroblasts Derived from ATM/ hESCs Lack
Irradiation-Induced Foci of g-H2AX after IR
(A) EB-mediated differentiation of hESCs into fibroblasts. Representative
images of hESCs, day 7 embryoid bodies (EBs), and fibroblasts derived
from EBs.
(B) Irradiation-induced foci (IRIF) of phosphorylated ATM and g-H2AX is
abolished in human fibroblasts derived ATM/ hESCs after IR. The nucleus
was counterstained with DAPI.
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hESCs. Similar to those derived fromWT hESCs, neural rosettes
that represent neural stem cells could be readily identified in the
teratomas derived from ATM/ hESCs (Figure 6A). In addition,
the mRNA expression of two neural markers, Neural cell adhe-
sion molecule 1 (NCAM1) and Phosphate-activated glutaminase
(GLS2), is similar in the teratomas derived from WT and ATM/
hESCs, suggesting that ATM is not required for the early human
neural development (Figure 6C). While the expression of the Pur-
kinje cell marker glutamate receptor delta-2 (GRID2) was
reduced in the teratomas derived from ATM/ hESCs when
compared with that in teratomas derived from WT hESCs, the
expression of two other potential Purkinje cell-specific markers
(CALB1 and ITPR1) was similar in ATM/ and WT teratomas
(Figure 6C). Once the conditions for differentiating hESCs into
Purkinje neurons are established, the ATM/ hESCs will be
used to further investigate the roles of ATM in the development
and maintenance of the Purkinje neurons.
Cells derived from A-T patients undergo accelerated telomere
shortening (Shiloh, 1995). Therefore, we examined the telomere
length in cells differentiated from WT and ATM/ hESCs. Since
teratoma generated from hESCs provides a comprehensive
mixture of differentiated cells, we determined the average telo-
mere length in the genomic DNA derived from teratomas gener-
ated by WT and ATM/ hESCs. Our findings indicate that the
average telomere length in WT teratomas is 20%–30% longer
than that in ATM/ teratomas, indicating the potential to employ
ATM/ hESCs to further study the roles of ATM in telomeremaintenance (Figures 6D and 6E). In summary, these findings
demonstrate the feasibility to employ genetically modified
hESCs and their capability to form teratomas in SCID mice for
in vivo modeling of human diseases.
p53-Dependent Function Is Abolished in p53/ hESCs
When injected into SCID mice, p53/ hESCs gave rise to tera-
tomas containing cells derived from each of the three germ
layers, indicating that these cells remained pluripotent (Fig-
ure S4). The generation of p53/ hESCs provides us the unique
opportunity to study the roles of p53 in DNA-damage responses
and genetic stability in hESCs. Compared with that in p53+/+
hESCs, p53-dependent induction of p21 and Noxa mRNAs, as
well as Mdm2, was abolished in p53/ hESCs after DNA
damage (Figures 7A and 2G). In addition, when compared with
those in WT hESCs, the basal levels of p21 expression in the
absence of DNA damage were also greatly reduced in p53/
hESCs (Figure 7A). Together, these data indicate that p53 is tran-
scriptionally active in hESCs and is greatly induced in hESCs
after DNA damage.
Nanog, a homeodomain protein required for the self-renewal
of ESCs, is an important coordinator of DNA-damage response
and self-renewal in ESCs (Xu, 2005). In this context, the expres-
sion of Nanog is suppressed directly by p53 in mouse ESCs after
DNA damage (Lin et al., 2005). Nanog expression is also reduced
in WT hESCs rapidly after DNA damage in a p53-dependent
manner, indicating an evolutionarily conserved role of p53 in
coordinating DNA-damage response and self-renewal in ESCs
(Figure 7B).
As an apparent difference between mouse and human cells,
p53 is required for the G2/M checkpoint in human cells after
DNA damage but dispensable for G2/M checkpoint in mouse
cells (Sancar et al., 2004; Song et al., 2007). Therefore, we inves-
tigated whether p53 is required for the G2/M checkpoint in
hESCs. Control WT hESCs undergo robust G2/M arrest after
IR, and this checkpoint is impaired in p53/ hESCs, indicating
that p53 plays a role in cell-cycle G2/M checkpoint in hESCs after
DNA damage (Figure 7C).
While ATM/ hESCs appear to be genetically stable, similarly
to p53/ somatic cells, chromosomal aneuploidy was observed
in a small fraction (10%–20%) of the p53/ hESCs (Figure S2C).
In this context, the deletion of the long armof chromosome 9was
observed in two of the twenty metaphases of each of the two
independently generated p53/ hESCs examined. In addition,
two metaphases exhibited the duplication of chromosome 17
and 20, respectively. Therefore, the increased spontaneous
genomic instability in p53/ hESCs suggests that p53 plays
an important role in maintaining genetic stability in hESCs.
DISCUSSION
hESCs can undergo unlimited self-renewal and be differentiated
into all cell types in the body. Therefore, efficient genetic manip-
ulation technology of hESCs will revolutionize our approach to
study the cellular and developmental functions of human genes.
By resolving the technical bottleneck to allow efficient gene
targeting through homologous recombination in hESCs, the
BAC-based gene targeting strategy will greatly facilitate the
research to genetically modify hESCs into human diseaseCell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc. 85
Figure 6. Teratomas Formation by ATM/
hESCs in SCID Mice
(A) Teratomas formed by WT and ATM/ hESCs
both contain the cell types derived from each of
the three embryonic germ layers. For example,
neural Rosette, adipocytes, and smooth muscle
(Aa); Skeletal muscle (Ab); gut and smooth muscle
(Ac); neural rosette and smooth muscle (Ad); bone
(Ae); and liver (Af).
(B) Representative image of teratomas formed by
the same number of ATM/ hESCs and WT
hESCs implanted in the same SCID mice. The
mean ratio of the weight of the three sets of
ATM/ tumor versus WT tumor is presented
with standard derivation.
(C) The ratio ofmRNA levels of neural cell adhesion
molecule 1 (NCAM1); glutaminase (GLS2); calbin-
din 1 (CALB1); inositol 1,4,5-triphosphate recep-
tor, type 1 (ITPR1); and glutamate receptor, iono-
tropic, delta 2 (GRID2) genes in ATM/
teratomas versus WT tumor. The mRNA levels of
each gene were determined by real-time PCR
and standardized by the mRNA levels of GAPDH.
Mean ratio from three sets of ATM/ and WT
tumors are shown with standard derivation.
(D) Southern blotting analysis of telomere length in the genomic DNA of four teratomas, two generated withWT hESCs and two by ATM/ hESCs. Genomic DNA
derived from teratomas was digested with HinfI and RsaI, and hybridized with telomere-specific digoxigenin (DIG)-labeled probe, which was detected by anti-
DIG-alkaline phosphatase and chemiluminescence. Molecular weight markers are indicated on the left.
(E) The average telomere length in ATM/ teratomas is shorter than that inWT teratomas. Mean telomere length was calculated from
P
ODi/(
P
ODi/
P
MWi). ODi
andMWi are optical density andmolecular weight at a given position i, respectively. The average telomere length of each teratomas is indicated next to the geno-
type. See also Figure S3.
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compared with the gene targeting strategy with the standard
targeting vector, the BAC based strategy has some obvious
advantages. First, while the standard targeting vector needs to
be generated with genomic DNA isogenic to the hESCs to allow
higher frequency of homologous recombination, the BAC-based
targeting vector derived from commercial sources can achieve
high efficiency of homologous recombination in hESCs of
various genetic backgrounds. In addition, while the generation
of the standard targeting vectors involves complex and some-
times technically difficult cloning strategies, the recombineering
technology in bacteria allows rapid genetic modification of the
BAC sequence. These advantages will enable timely generation
of BAC-targeting vectors for high efficiency gene targeting in
hESCs. However, considering the large size of the homologous
arms in the BAC targeting vector, one drawback for the BAC-
based targeting approach is the difficulty to confirm the homol-
ogous recombination event. This problem is partially mitigated
by our strategy to shorten one of the homologous arms with
recombineering to allow the confirmation of the proper targeting
with Southern blotting.
Recent advances of using zinc-finger nuclease (ZFN)-medi-
ated genome editing has also enabled high efficiency of genetic
manipulation in hESCs (Hockemeyer et al., 2009; Zou et al.,
2009). When compared with the ZFN-mediated strategy, the
BAC-based strategy might offer two potential advantages.
First, the success of the ZFN-mediated strategy depends on
the design of zinc finger motifs that can specifically bind to
the endogenous genomic sequences around the targeting
loci. This could be a time-consuming task since the designed
zinc finger needs to be experimentally optimized for the high86 Cell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc.binding specificity for the target sequence. In this context,
the DNA-binding specificity of the designed zinc finger proteins
in cells remains to be validated with vigorous genomic analysis,
such as ChIP-Seq technology. Therefore, to avoid the binding
of designed zinc finger proteins to the unexpected locations
in the genome would be a technical bottleneck for the
ZFN-mediated strategy. This ‘‘off-target’’ effect of the designed
ZFN would be even more problematic when the targeted genes
are involved in maintaining genomic stability in hESCs, because
multiple double-strand breaks introduced by ZFN in the
genome will promote chromosomal translations, especially
when the DNA damage response pathways are disrupted
(Shiloh, 2003).
Recent groundbreaking discovery that somatic cells can be
reprogrammed into the induced pluripotent stem cells (iPSCs)
with defined factors has provided tremendous potential for
developing human disease models (Dimos et al., 2008; Ebert
et al., 2009; Takahashi and Yamanaka, 2006). While iPSCs
provide a unique opportunity to model human diseases with
unknown or complex genetic traits, iPSC technology might not
be suitable to develop disease models for human genetic insta-
bility syndromes, such as the ones reported here, because the
adult somatic cells derived from such patients will have already
harbored cell-specific genetic alterations, preventing their use
as generic disease models. In addition, based on the findings
that the reprogramming factors mostly have oncogenic potential
and that tumor suppression pathways appear to inhibit the
reprogramming (Krizhanovsky and Lowe, 2009; Deng and Xu,
2009), the genetic stability and tumorigenic potential of iPSCs
needs to be vigorously investigated before their potential in
drug discovery can be fully realized.
Figure 7. p53-Dependent Functions Are Abolished in p53/ hESCs
(A) p53-dependent expression of p21 and Noxa mRNA is abolished in p53/
hESCs after DNA damage induced by Doxorubicin. The mRNA levels of each
gene were determined by real-time PCR and standardized by themRNA levels
of GAPDH.
(B) p53-dependent suppression of Nanog expression is abolished in p53/
hESCs after DNA damage. Mean values from three independent experiments
are shown with standard derivation.
(C) G2/M checkpoint is impaired in p53
/ hESCs after IR. Mean values from
three independent experiments are shown with standard derivation. p value
between the irradiated WT and p53/ hESCs is shown. Consistent data
were obtained from two independent p53/ hESCs. See also Figure S4.
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genetic stability and tumor suppression (Xu, 2006), the ATM/
and p53/ hESCs we established will become valuable
resources to study human tumorigenesis and develop more
effective therapeutic interventions for human cancer. Our
studies of the ATM/ hESCs indicate that, despite their defects
in DNA repair and cell-cycle checkpoint, ATM/ hESCs remain
genetically stable. Since ATM/ human somatic cells exhibit
extensive genomic instability (Shiloh, 2003), this finding further
highlights the existence of distinct mechanisms involved inmain-
taining genomic stability in hESCs and somatic cells. In addition,
while our data suggest that p53 is important in maintaining
genomic stability in both hESCs and somatic cells, the functions
of p53 in hESCs might be different from those in somatic cells.
In this context, some of the well-established p53 functions
in somatic cells, such as cell-cycle G1/S checkpoint, cellular
senescence, and apoptosis, do not operate efficiently in ESCs
(Xu, 2005). Therefore, similarly to that in mouse ESCs (Lin
et al., 2005), one important role of p53 in maintaining genomic
stability in hESCs could be to suppress Nanog expression after
DNA damage, leading to the differentiation of DNA damaged
hESCs and, thus, maintaining the genomic stability in the self-
renewing hESCs.
EXPERIMENTAL PROCEDURES
Construction of BAC-Based Targeting Vectors
The BAC clones were from the RPCI-11 Human Male BAC Library (Osoegawa
et al., 2001) and purchased from Invitrogen. The BAC based targeting vectorwas generated with recombineering (Copeland et al., 2001). E. coli strain
SW106 was transformed with BAC DNA spanning human ATM, p53, or
HPRT locus (Warming et al., 2005). To allow the efficient expression of the
selection markers in hESCs, the PGK promoter of the selection markers was
replaced with CMV early enhancer/chicken b actin (CAG) promoter that is
highly active in hESCs. For the secondary targeting in hESCs, the IRES-Puro
DNA fragment was inserted between the Neo and PolyA signal so that Neo
and Puro are expressed simultaneously. About one kb homologous arms
were inserted on the 50 and 30 of the selection cassettes, which was trans-
fected into the SW106 harboring the ATM or p53 BAC to allow the insertion
of the selection cassette into the BAC through homologous recombination.
To shorten one homologous arm of the BAC targeting vector, AmpR genes
flanked by 0.5 kb of target sequence from the homologous arm and 0.5 kb
of a sequence from the backbone were introduced into the recombineering
bacterial harboring the BAC-targeting vector. Homologous recombination
will replace the genomic DNA of the BAC between the target sequence and
backbone with AmpR gene and, thus, confer resistance to ampicillin to the
bacteria.
Culture and Treatment of hESCs
The HUES cells were cultured on feeder layer in knockout DMEM supple-
mented with 10% knockout serum replacement (KSR), 10% plasmanate,
PenStrep, Glutamine, nonessential amino acids, 10 ng/ml bFGF, and 55 mM
b-mecaptoethanol, as described (Cowan et al., 2004). To culture the hESCs
in the absence of feeder layer, the hESCs were cultured on matrigel-treated
plates in the TESR medium supplemented with MEF conditional medium. All
tissue culture reagents are purchased from Invitrogen. For passaging hESCs,
confluent culture was washed with PBS, trypsinized for 5 min, resuspended in
culture medium into single cell, and plated at 1:5 to 1:8 ratios.
For the electrophoration of BAC vectors into hESCs, 20 million hESCs were
washed twicewith PBS andmixedwith 100 mg of DNA for 5min on ice. Electro-
poration was conducted with a Biorad Gene Pulser II (320 V, 200 mF). The
transfected cells were plated on feeder layer and, 2 days later, selected with
G418 (50 mg/ml) or Puromycin (0.5 mg/ml). Surviving colonies were individually
picked and expanded.
H9 cells were maintained as previously described (Thomson et al., 1998).
Two hours before dissociating with Accutase (Millipore), H9 cells were treated
with 10 mM ROCK inhibitor Y-27632 (Calbiochem). After electroporation
with the BAC targeting vector, transfected cells were incubated with 10 mM
Y-27632 for 24 hr.
All human ESC work has been approved by UCSD ESCRO and IRB.
Karyotyping and SNP-CGH Analysis
Karyotyping of the mutant hESC clones was carried out by Cell Line Genetics
(Madison, WI). SNP-CGH analysis was carried out by Expression Analysis, Inc.
(Durham, NC).
Taqman PCR Assay to Detect ATM Gene Copy Number
Real-time PCR reaction was carried out with 5 ng of genomic DNA, 250 nM of
Taqman probes, and 500 nM of primers. Sequences of primers are as follows:
GAPDHF, 50-CCC CAC ACA CAT GCA CTT ACC-30; GAPDHR, 50-CCT AGT
CCC AGG GCT TTG ATT-30; GAPDH probe, 50-(HEX) AAA GAG CTA GGA
AGG ACA GGC AAC TTG GC (IOWA BLACK FQ)-30, ATMF, 50- TCA TCA
GCT TTG CAG GCA TTA T-30;ATMR, 50-TGC AAA TGC TGG AAC AAC
ATG-30; and ATM probe, 50-(FAM) TAA TTG TTG CAC CCA TTC TCC AA
(IOWA BLACK FQ)-30.
Radiosensitivity Assay of hESCs
hESCs were plated on feeder layer in 12-well plate with a density of 2000 cells/
well. One day after plating, the cells were mock-treated or treated with
increasing dosages of IR. After 2 weeks, the surviving colonies were stained
with crystal violet and counted.
Teratoma Formation in SCID Mice
Two to three million hESCs were suspended in the knockout medium supple-
mented with 30%matrigel (BD Biosciences) and injected subcutaneously into
SCID mice. Teratomas were recovered 6 weeks after implantation, fixed in
10% buffered formalin, embedded in paraffin, and sectioned. All sectionsCell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc. 87
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ously described (Chao et al., 2006). All animal work has been approved by
UCSD IACUC.EB Formation and EB-Mediated Differentiation into Human
Fibroblast
Subconfluent hESCs were washed with PBS, treated with 1 mg/ml collage-
nase type IV for 10 min at 37C, and harvested with a cell scraper. After the
dissociation with pipetting, cells were grown on a low-binding plate in medium
consisting of KO-DMEM, 20% knockout serum replacement (KSR), nonessen-
tial amino acids, glutamine, penicillin/streptomycin, and 0.55 mM b-mercap-
toethanol. Since embryoid bodies (EBs) are growing in suspension, half of
the medium was changed every other day.
To derive fibroblasts from hESCs, the EBs with 7 days of suspension culture
were seeded onto gelatin-coated tissue culture plates in differentiation
medium consisted of DMEM supplemented with glutamine and 10% (v/v) fetal
calf serum (FCS). Four to five days after initial seeding of the EBs, a confluent
monolayer was trypsinized and passaged on gelatin-coated plates.Western Blotting Analysis
Protein extracts were resolved on 6%–10%SDS-PAGE gels and transferred to
nitrocellulose membrane, which was probed with a monoclonal antibody
against p53 (pAb1801; Santa Cruz Biotechnology, Santa Cruz, CA) or poly-
clonal antibody against b-actin (Santa Cruz Biotechnology) or monoclonal
antibody against ATM (Rockland, Gilbertsville, PA). Phosphorspecific anti-
bodies were purchased from Cell Signaling Technology (Danvers, MA). The
membrane was subsequently probed with a horseradish peroxidase-conju-
gated secondary antibody and developed with ECL PLUS (Amersham, Piscat-
away, NJ).Cell-Cycle Analysis
Cell cycle G2/M checkpoint was analyzed as previously described (Song et al.,
2007). Asynchronously growing hESCswere irradiatedwith various dosages of
IR and harvested 1 hr after IR. Cells in mitosis were identified by staining with
propidium iodide for DNA content and an FITC-conjugated antibody recog-
nizing histone H3 phosphorylated at Ser 10 (Upstate, Charlottsville, VA).Quantitative Real-Time PCR
Total RNA from hESCs or fibroblasts was isolated using Trizol (Invitrogen,
Carlsbad, CA) and RNAeasy Mini Kit (QIAGEN, Valencia, CA). One microgram
of total RNAwas reverse-transcribed using Superscript II RT (Invitrogen). Real-
time PCR was performed with an ABI Prism 7000 (Applied Biosystems, Foster
City, CA) with Power SyberGreen PCR Master Mix (Applied Biosystems,
Foster City, CA). The PCRconditionswere as follows: 10min at 95C, 40 cycles
of 15 s at 95C, and 1 min at 60C. The average Ct value for each gene was
determined from triplicate reactions and normalized with the levels of GAPDH
as previously described (Song et al., 2007). The sequence of the primers are as
follows: Calb1 50ACAGTGGCTTCATAGAAACTGAG30, 50CCACACATTTTG
ATTCCCTGGA30; GLS2 50TCTTCCGAAAGTGTGTGAGCA30, 50GACATCCTC
AAAGATGCGATCC30; GRID2 50CTCTTGGTTTTGTCCGTCTGG30, 50GCAGT
GCGAAATACCTCATCATC30; ITPR1 50TCCAGCATGACCCATGTCG30, 50CAC
TGAGGGCTGAAACTCCAG30; NCAM1 50TCTATAACGCCAACATCGACGA30,
50TTGGCGCATTCTTGAACATG30.Immunoflourescence Microscopy
Human fibroblasts grown on coverslip were exposed to 2 Gy g-irradiation and
30min later fixed with methanol:acetone (50:50) for 10min at20C. The fixed
cells were blocked with 3% BSA in PBS and incubated with mouse mono-
clonal antibody specific for phosphorylated ATM at 1981 (1:600 dilution) or
a rabbit polyclonal phosphor-specific antibody against H2AX-139p (1:200) in
1% BSA in PBS overnight at 4C. After washing, the cells were incubated
with secondary antibodies for 1 hr at room temperature. After mounting
on glass slides with VECTASHIELD mounting media with DAPI (Vector Lab-
oratories, Burlingame, CA), images were acquired by Olympus confocal
microscope.88 Cell Stem Cell 6, 80–89, January 8, 2010 ª2010 Elsevier Inc.TRF Assay
TRF (Terminal Restriction Fragments) assaywas performed using Telo TAGGG
Telomere Length Assay as instructed by the manufacturer (Roche, NJ). Chem-
iluminscent signal was scanned by Typhoon Trio and analyzed by Imagequant
TL software (GE Healthcare). Mean TRF length was calculated from
P
ODi/
(
P
ODi/
P
MWi). ODi and MWi are optical density and molecular weight at
a given position i, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.stem.2009.11.016.
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